All News

This phase 1 study found that vorinostat (Zolinza) in combination with either sirolimus (Rapamune) or everolimus (Afinitor) demonstrated clinical efficacy in patients with relapsed and/or refractory Hodgkin lymphoma and warrants further investigation.

The FDA approved an expanded label for pembrolizumab (Keytruda) as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.

New research reported that guidelines to reduce the number of opioids prescribed to patients following surgery may be missing a small group of patients that need a greater level of pain control.

This study found that immune checkpoint inhibitor therapy in patients with cancer could aggravate cardiovascular inflammation and subsequent cardiovascular or cerebrovascular events.

The study is evaluating copanlisib (Aliqopa) in combination with rituximab (Rituxan) in patients with indolent non-Hodgkin’s lymphoma who have relapsed after 1 or more prior lines of rituximab-containing therapy.

The latest episode of Oncology Peer Review On-The-Go explores an article from the September issue of the journal ONCOLOGY regarding the psychological states of patients enrolling in phase 1 clinical trials.

After adjustments for a number of clinical factors and factors related to access to care, the overall survival disparity among men undergoing radical prostatectomy was significantly decreased, but not eliminated, for Black men.

“In light of these findings, black patients with cancer should exercise more caution and consistently use strategies to prevent COVID-19 infection,” Chintan Pandya, MD, PhD, said in a press release.

Researchers indicated it is important to recognize these disparities that exist among racial and ethnic minorities in order to ensure routine and follow-up cancer care is delivered, even during the COVID-19 pandemic.

Among accredited US cancer centers, hospitals which serve primarily minority patients were found to be as likely as other hospitals to offer the standard of surgical care for early-stage breast cancer.

Natera announced the DARE trial examining Palbociclib to treat patients with advanced breast cancer will use its Signatera molecular residual disease test.

According to findings from the ASCO Quality Care Symposium, Black and Hispanic patients with cancer may be more likely to be infected with COVID-19 than white patients.

Though this study did not determine the causality, it clearly demonstrated an association between atopy and immune thrombocytopenic purpura (ITP).

“This is the first trial to report objective responses in patients with advanced urothelial cancer who had previously received immunotherapy but were ineligible for cisplatin in this setting due to inadequate kidney function or other conditions,” Roger Dansey, MD, said in a press release.

A study published in The BMJ concluded that a single dose of targeted radiotherapy was just as effective as conventional radiotherapy for women with early breast cancer.

This study found that cancer mortality was higher in counties that experienced persistent poverty compared to other counties, including those currently experiencing poverty.

The inherited GATA3 variant rs3824662 was found to strongly influence response to remission induction therapy in childhood acute lymphoblastic leukemia and was also associated with relapse.

Research suggested that limited English-language proficiency is a risk factor for getting potentially lifesaving screening mammograms less often.

Researchers suggested that a scoring system may aid in determining the appropriate use of HSCT in this patient population.

This study suggested that the customized bioinformatics workflow, UroCAD, be used as a noninvasive approach for diagnosis and recurrence surveillance in patients with urothelial carcinoma prior to the use of cystoscopy.

The trial did not meet its primary end point of improved invasive disease-free survival in women with hormone receptor-positive HER2-negative early breast cancer who have residual invasive disease after completing neoadjuvant chemotherapy.

Researchers found that patients who participated in virtual follow-up visits benefitted by spending less time waiting at and traveling to the clinic for in-person appointments.

According to researchers, these results will be important for understanding what factors may be driving mutations in a given cancer and may also possibly point to new therapeutic targets.

A study published in the Journal of Clinical Oncology found that rucaparib can successfully treat patients with metastatic castration-resistant prostate cancer who have mutated BRCA/BRCA2 genes.

Researchers suggested these findings may assist in better selection and prioritization of immune checkpoint inhibitor agents for testing in randomized clinical trials based on phase 2 single arm randomized clinical trial results.

This study found that single dose-per-cycle plinabulin has a similar neutropenia protection benefit as pegfilgrastim among adult patients with non-small cell lung cancer.

Researchers identified molecular and cellular characteristics of anti-CD19 CAR T-cell infusion products associated with how patients with large B-cell lymphoma respond to treatment and experience adverse events.

Significantly more patients treated with nivolumab (Opdivo) plus chemotherapy before surgery demonstrated no evidence of cancer cells in their resected tissue in the trial compared to those treated with chemotherapy alone.

Moss indicated that “we need interventions in these communities to change cancer-causing behaviors, to make cancer screening more accessible, to improve treatment, and to promote quality of life and survivorship.”

This data suggests clinicians should not rely on self-reports from their patients about either their need or the proper interval for a repeat surveillance colonoscopy.